Results 21 to 30 of about 291 (113)

Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.

J Clin Endocrinol Metab, 2023
Abstract Context The pretreatment blood transcriptome predicts growth response to daily growth hormone (GH) therapy with high accuracy. Objective Investigate response prediction using pretreatment transcriptome in children with GH ...
Garner T, Clayton P, Højby M, Murray P, Stevens A.   +4 more
europepmc   +6 more sources

Somapacitan in children born small for gestational age: 4-year results from phase 2

European Journal of Endocrinology
Abstract Objective Evaluate long-term efficacy, safety, and tolerability of once-weekly somapacitan, a long-acting growth hormone (GH) derivative, in children born small for gestational age (SGA) with short stature, including after switching from daily GH.
Anders Juul, Jun Mori
exaly   +4 more sources

What do we do now that the long-acting growth hormone is here?

Frontiers in Endocrinology, 2022
In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj   +1 more source

Safety and efficacy of weekly somapacitan for growth hormone deficiency in children: A 72-week observational study. [PDF]

Saudi Med J
To assess the effectiveness and safety of somapacitan, a long-acting growth hormone analog, as a promising treatment to improve adherence in pediatric growth hormone deficiency (GHD) management.The observational study included 184 children diagnosed with GHD.
Al-Agha AE, Aljefri HM, Kafi SE, Alamri AS, Alghamdi AA.   +4 more
europepmc   +3 more sources

Growth hormone receptor agonists and antagonists: From protein expression and purification to long‐acting formulations

Protein Science, Volume 32, Issue 9, September 2023., 2023
Abstract Recombinant human growth hormone (rhGH) and GH receptor antagonists (GHAs) are used clinically to treat a range of disorders associated with GH deficiency or hypersecretion, respectively. However, these biotherapeutics can be difficult and expensive to manufacture with multiple challenges from recombinant protein generation through to the ...
Yue Wang, Minah Kim, Chantal Buckley, Heather D. Maynard, Ries J. Langley, Jo K. Perry   +5 more
wiley   +1 more source

Seven-year Safety and Efficacy of Somapacitan in Children With GH Deficiency: Final Results From REAL 3. [PDF]

J Endocr Soc
Abstract Background Somapacitan is a once-weekly GH treatment that has shown efficacy and safety profiles equivalent to daily GH in children with GH deficiency (GHD). Objective To investigate long-term safety ...
Sävendahl L, Battelino T, Højby M, Leunbach T, Saenger P, Silverman L, Horikawa R.   +6 more
europepmc   +4 more sources

Long‐acting growth hormone in 2022

Pediatric Investigation, Volume 7, Issue 1, Page 36-42, March 2023., 2023
After successful clinical use of growth hormone (GH) for nearly 70 years, we are now able to use long‐acting GH (LAGH) with identical or even slightly greater efficacy in clinical medicine in GH deficiency in children and adults. ABSTRACT After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the ...
Margaret Steiner, Jacklyn Frank, Paul Saenger   +2 more
wiley   +1 more source

Annual banned‐substance review—Analytical approaches in human sports drug testing 2021/2022–

Drug Testing and Analysis, Volume 15, Issue 1, Page 5-26, January 2023., 2023
Detection assays for drugs and methods of sports doping published between 2021 and 2022 are critically reviewed and evaluated in context with the Prohibited List 2022 as established by the World Anti‐Doping Agency. Abstract Also in 2021/2022, considerable efforts were invested into advancing human sports drug testing programs, recognizing and taking ...
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency

European Journal of Endocrinology, 2022
Abstract Objective Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose–responses among patients. The aim of this study was to provide clinical guidance on dosing and titration of the novel long-acting GH ...
Rasmus Juul Kildemoes, Christian Hollensen, Beverly M K Biller, Gudmundur Johannsson, Yutaka Takahashi, Michael Højby Rasmussen   +5 more
openaire   +2 more sources

Identification of Binding Sites on Human Serum Albumin for Somapacitan, a Long-Acting Growth Hormone Derivative [PDF]

Biochemistry, 2020
Somapacitan, a human growth hormone derivative that binds reversibly to albumin, was investigated for human serum albumin (HSA) and HSA domain binding. Isothermal titration calorimetry (ITC) binding profiles showed high-affinity binding (∼100-1000 nM) of one somapacitan molecule and low-affinity binding (∼1000-10000 nM) of one to two somapacitan ...
Eva Johansson, Anders D. Nielsen, Helle Demuth, Charlotte Wiberg, Christine B. Schjødt, Tao Huang, Jianhe Chen, Sanne Jensen, Jørgen Petersen, Peter Thygesen   +9 more
openaire   +2 more sources